Advertisement

American Journal of Cardiovascular Drugs

, Volume 9, Issue 3, pp 149–162 | Cite as

A Guide to the Management of Blood Pressure in the Diabetic Hypertensive Patient

  • Nicolas W. ShammasEmail author
  • Domenic A. Sica
  • Peter P. Toth
Therapy in Practice

Abstract

Diabetes mellitus and hypertension frequently coexist in patients with the insulin resistance syndrome (IRS). Patients with both diabetes and hypertension typically have widespread endothelial dysfunction, increased oxidative stress, an activated sympathoadrenal system, and an elevated systemic burden of inflammatory mediators. Patients with diabetes and hypertension also have concomitant mixed dyslipidemia and obesity with significant frequency, and are at high risk for the development of macro- and microvascular disease, congestive heart failure, and nephropathy. Current data suggest that ACE inhibitors or angiotensin receptor blockers with or without a diuretic are important, if not preferred, initial therapies for the patient with diabetes and hypertension. Other drug classes such as combined α-/β-adrenoceptor antagonists, dihydropyridine calcium channel antagonists (CCAs), and peripheral α-adrenoceptor antagonists are also useful therapeutic options in these patients. In order to optimally reduce the risk for cardiovascular events in the patient with diabetes and hypertension, optimal BP control should be coupled with comprehensive lifestyle modification and aggressive management of dyslipidemia and hyperglycemia.

Keywords

Diabetic Nephropathy Amlodipine Carvedilol Angiotensin Receptor Blocker Irbesartan 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Nicolas W. Shammas has received honoraria and educational grants (via the Midwest Cardiovascular Research Foundation) from Astra Zeneca, GlaxoSmithKline, Wyeth, Merck, and Schering-Plough. Dr Shammas has no stocks, investments or patent pending with these corporations. Domenic A. Sica has received consultancies and honoraria form Novartis, Boehringer-Ingelheim, and GlaxoSmithKline. Dr Sica has received grants from Novartis. Peter P. Toth has received honoraria and grants from Merck, and Novartis. Dr Toth has received consultancies from Merck. No funding was used to prepare this review.

References

  1. 1.
    Korhonen P, Aarnio P, Saaresranta T, et al. Glucose homeostasis in hypertensive subjects. Hypertension 2008; 51: 945–9.PubMedGoogle Scholar
  2. 2.
    Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374–81.PubMedGoogle Scholar
  3. 3.
    Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25: 391–406.PubMedGoogle Scholar
  4. 4.
    Golomb BA, Dimsdale JE, White HL, et al. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med 2008; 168: 721–7.PubMedGoogle Scholar
  5. 5.
    Welborn TA, Breckenridge A, Rubinstein AH, et al. Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet 1966; 1: 1136–7.Google Scholar
  6. 6.
    Swislocki ALM, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989; 2: 419–23.PubMedGoogle Scholar
  7. 7.
    Ferrannini E, Buzzigoli G, Bonadona R. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–7.PubMedGoogle Scholar
  8. 8.
    Ferrannini E, Natali A, Capaldo B, et al., For the European Group for the Study of Insulin Resistance (EGIR). Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. Hypertension 1992; 30: 1144–9.Google Scholar
  9. 9.
    Lissner L, Bengtsson C, Lapidus L, et al. Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension 1992; 20:797–801.PubMedGoogle Scholar
  10. 10.
    Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97.Google Scholar
  11. 11.
    Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101: 975–80.PubMedGoogle Scholar
  12. 12.
    Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840–4.PubMedGoogle Scholar
  13. 13.
    Festa A, D’Agostino Jr R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42–7.PubMedGoogle Scholar
  14. 14.
    Trepels T, Zeiher AM, Fichtlscherer S. The endothelium and inflammation. Endothelium 2006; 13: 423–9.PubMedGoogle Scholar
  15. 15.
    Dogra G, Irish A, Chan D, et al. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis 2006; 48: 926–34.PubMedGoogle Scholar
  16. 16.
    Khosla N, Sarafidis PA, Bakris GL. Microalbuminuria. Clin Lab Med 2006; 26: 635–53.PubMedGoogle Scholar
  17. 17.
    Hypertension in Diabetes Study Investigators. Hypertension in Diabetes Study (HDS): II, increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319–25.Google Scholar
  18. 18.
    Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001; 322 (7277): 15–8.PubMedGoogle Scholar
  19. 19.
    Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321 (7258): 405–12.PubMedGoogle Scholar
  20. 20.
    Laasko M. Benefits of strict glucose and blood pressure control in type 2 diabetes: lessons from the UK Prospective Diabetes Study. Circulation 1999; 99: 461–2.Google Scholar
  21. 21.
    Abbott RD, Donahue RP, Kannel WB, et al. The impact of diabetes on survival following myocardial infarction in men versus women: the Framingham Study. JAMA 1988; 260: 3456–60.PubMedGoogle Scholar
  22. 22.
    Gilbert RE, Kim C, Kelly DJ, et al. Heart failure and nephropathy: catastrophic and interrelated complications of diabetes. Clin J Am Soc Nephrol 2006; 1: 193–208.PubMedGoogle Scholar
  23. 23.
    Cohn JN. New therapeutic strategies for heart failure: left ventricular remodeling as a target. J Card Fail 2004; 10 (6 Suppl.): S200–1.PubMedGoogle Scholar
  24. 24.
    Pieske B, Wachter R. Impact of diabetes and hypertension on the heart. Curr Opin Cardiol 2008; 23: 340–9.PubMedGoogle Scholar
  25. 25.
    Ingelsson E, Sundstrom J, Arnlov J, et al. Insulin resistance and risk of congestive heart failure. JAMA 2005; 294: 334–41.PubMedGoogle Scholar
  26. 26.
    Wright Jr JT, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med 2008; 168: 207–17.PubMedGoogle Scholar
  27. 27.
    Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412–9.PubMedGoogle Scholar
  28. 28.
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–62.PubMedGoogle Scholar
  29. 29.
    Cushman WC, Grimm Jr RH, Cutler JA, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99 (12A): 441–551.Google Scholar
  30. 30.
    Franco V, Oparil S. Salt sensitivity, a determinant of blood pressure, cardiovascular disease and survival. J Am Coll Nutr 2006; 25 (3 Suppl.): 247S–55S.PubMedGoogle Scholar
  31. 31.
    Strojek K, Nicod J, Ferrari P, et al. Salt-sensitive blood pressure: an intermediate phenotype predisposing to diabetic nephropathy? Nephrol Dial Transplant 2005; 20: 2113–9.PubMedGoogle Scholar
  32. 32.
    Dodson PM, Beevers M, Hallworth R, et al. Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. Brit Med J 1989; 298: 227–30.PubMedGoogle Scholar
  33. 33.
    Sturrock ND, George E, Pound N, et al. Non-dipping circadian blood pressure and renal impairment are associated with increased mortality in diabetes mellitus. Diabet Med 2000; 17: 360–4.PubMedGoogle Scholar
  34. 34.
    Czupryniak L, Pawłowski M, Saryusz-Wolska M, et al. Circadian blood pressure variation and antihypertensive medication adjustment in normoalbuminuric type 2 diabetes patients. Kidney Blood Press Res 2007; 30:182–6.PubMedGoogle Scholar
  35. 35.
    Minutolo R, Gabbai FB, Borrelli S, et al. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am J Kidney Dis 2007; 50: 908–17.PubMedGoogle Scholar
  36. 36.
    Medow MS, Stewart JM, Sanyal S, et al. Pathophysiology, diagnosis, and treatment of orthostatic hypotension and vasovagal syncope. Cardiol Rev 2008; 16: 4–20.PubMedGoogle Scholar
  37. 37.
    Chobanian AV, Bakris GL, Black HR, et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560–72.PubMedGoogle Scholar
  38. 38.
    American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31 Suppl. 1: S12–54.Google Scholar
  39. 39.
    Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410–9.PubMedGoogle Scholar
  40. 40.
    Turnbull F, Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–35.PubMedGoogle Scholar
  41. 41.
    Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000; 18: 1671–5.PubMedGoogle Scholar
  42. 42.
    Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calciumchannel blocker or diuretic in the International Nifedipine GITS study: intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.PubMedGoogle Scholar
  43. 43.
    Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–65.PubMedGoogle Scholar
  44. 44.
    Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).ALLHAT Collaborative Research Group. Arch Intern Med 2005; 165 (12): 1401–9.PubMedGoogle Scholar
  45. 45.
    Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47: 352–8.PubMedGoogle Scholar
  46. 46.
    Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002; 62: 243–62.Google Scholar
  47. 47.
    Sica DA. Thiazide-type diuretics and their use in hypertension: con position. J Clin Hypertens 2005; 7: 117–20.Google Scholar
  48. 48.
    Alderman MH. New onset diabetes during antihypertensive therapy. Am J Hypertens 2008; 21: 493–9.PubMedGoogle Scholar
  49. 49.
    Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol 1996; 77: 1273–7.PubMedGoogle Scholar
  50. 50.
    UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–20.Google Scholar
  51. 51.
    Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. LIFE Study Group. Lancet 2002; 359: 1004–10.PubMedGoogle Scholar
  52. 52.
    Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. ASCOT Investigators. Lancet 2005; 366: 895–906.PubMedGoogle Scholar
  53. 53.
    Ostergren J, Poulter NR, Sever PS, et al. The anglo-scandinavian cardiac outcomes trial: blood pressure-lowering limb: effects in patients with type II diabetes. ASCOT investigators. J Hypertens 2008; 26 (11): 2103–11.PubMedGoogle Scholar
  54. 54.
    Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684–9.PubMedGoogle Scholar
  55. 55.
    Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–53.PubMedGoogle Scholar
  56. 56.
    Goldstein S. β-Blockers in hypertensive and coronary heart disease. Arch Intern Med 1996; 156: 1267–76.PubMedGoogle Scholar
  57. 57.
    Fonarow GC. Practical considerations of beta-blockade in the management of the post-myocardial infarction patient. Am Heart J 2005; 149: 984–3.PubMedGoogle Scholar
  58. 58.
    Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007; 100: 1254–62.PubMedGoogle Scholar
  59. 59.
    Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. GEMINI Investigators. JAMA 2004; 292: 2227–36.PubMedGoogle Scholar
  60. 60.
    Sica DA. Pharmacotherapy review: calcium channel blockers. J Clin Hypertens (Greenwich) 2006; 8: 53–6.Google Scholar
  61. 61.
    Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich) 2008; 10 (1 Suppl. 1): 27–32.Google Scholar
  62. 62.
    Jamerson KA, Weber MA, Bakris GL. Avoiding cardiovascular events through combination therapy in patients living with systolic hypertension: the early termination of the ACCOMPLISH trial for efficacy. Session 407, ACC 57th Annual Scientific Session; 2008 Mar 29–Apr 1; Chicago (IL).Google Scholar
  63. 63.
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. Collaborative Study Group. N Engl J Med 2001; 345: 851–60.PubMedGoogle Scholar
  64. 64.
    Bakris GL, Weir MR, DeQuattro V, et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283–9.PubMedGoogle Scholar
  65. 65.
    Segura J, García-Donaire JA, Ruilope LM. Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy? Curr Opin Nephrol Hypertens 2007; 16: 422–6.PubMedGoogle Scholar
  66. 66.
    Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Int Med 2003; 138: 593–602.PubMedGoogle Scholar
  67. 67.
    Sica DA. Pharmacotherapy review: angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) 2005; 7: 485–8.Google Scholar
  68. 68.
    Garg R, Yusuf S, For the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–6.PubMedGoogle Scholar
  69. 69.
    Shekelle PG, Rich MW, Morton SC, et al. Efficacy of ACE inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41: 1529–38.PubMedGoogle Scholar
  70. 70.
    ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic review of individual data from 100000 patients in randomized trials. Circulation 1998; 97: 2202–12.Google Scholar
  71. 71.
    Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53.PubMedGoogle Scholar
  72. 72.
    Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). EUROpean trial on reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Lancet 2003; 362: 782–8.PubMedGoogle Scholar
  73. 73.
    Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456–62.PubMedGoogle Scholar
  74. 74.
    Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45: S150–5.PubMedGoogle Scholar
  75. 75.
    Viberti G, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271: 275–9.PubMedGoogle Scholar
  76. 76.
    Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329: 828–39.PubMedGoogle Scholar
  77. 77.
    Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. Diabetics Exposed to Telmisartan and Enalapril Study Group. N Engl J Med 2004; 351: 1952–61.PubMedGoogle Scholar
  78. 78.
    Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). DIABHYCAR Study Investigators. BMJ 2004; 328: 495.Google Scholar
  79. 79.
    Mann JF, Gerstein HC, Yi QL, et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14: 641–7.PubMedGoogle Scholar
  80. 80.
    Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. ONTARGET investigators. Lancet 2008 Aug 16; 372 (9638): 547–53.PubMedGoogle Scholar
  81. 81.
    Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28–31.PubMedGoogle Scholar
  82. 82.
    UKPDS 69. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus. Arch Ophthalmol 2004; 122: 1631–40.Google Scholar
  83. 83.
    Douketis JD, Sharma AM. The management of hypertension in the overweight and obese patient: is weight reduction sufficient? Drugs 2004; 64: 795–803.PubMedGoogle Scholar
  84. 84.
    Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. Second Australian National Blood Pressure Study Group. N Engl J Med 2002; 348: 583–92.Google Scholar
  85. 85.
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 1981–97.Google Scholar
  86. 86.
    Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group. Arch Intern Med 2006; 166 (20): 2191–201.PubMedGoogle Scholar
  87. 87.
    Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. HOPE Study Investigators. JAMA 2001; 286: 1882–5.PubMedGoogle Scholar
  88. 88.
    Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6.PubMedGoogle Scholar
  89. 89.
    Lindholm LH, Ibsen H, Borch-Johnsen K, et al., For the LIFE study group. Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879–86.PubMedGoogle Scholar
  90. 90.
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. VALUE trial group. Lancet 2004; 363: 2022–31.PubMedGoogle Scholar
  91. 91.
    Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM overall programme. CHARM Investigators and Committees. Lancet 2003; 362:759–68.PubMedGoogle Scholar
  92. 92.
    Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369 (9557): 201–7.PubMedGoogle Scholar
  93. 93.
    Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463–73.PubMedGoogle Scholar
  94. 94.
    Sica DA. Pharmacotherapy review: angiotensin receptor antagonists. J Clin Hypertens (Greenwich) 2005; 7: 681–4.Google Scholar
  95. 95.
    Kjeldsen SE, Julius S, Mancia G, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. VALUE Trial Investigators. J Hypertens 2006; 24: 1405–12.PubMedGoogle Scholar
  96. 96.
    Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. N Engl J Med 2001; 345: 870–8.PubMedGoogle Scholar
  97. 97.
    Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. RENAAL Study Investigators. N Engl J Med 2001; 345: 861–9.PubMedGoogle Scholar
  98. 98.
    Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Irbesartan Diabetic Nephropathy Trial Collaborative Study Group. Ann Intern Med 2003; 138: 542–9.PubMedGoogle Scholar
  99. 99.
    Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators. N Engl J Med 2008; 358: 1547–59.PubMedGoogle Scholar
  100. 100.
    Reboldi G, Angeli F, Cavallini C, et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008;26(7):1282–9.PubMedGoogle Scholar
  101. 101.
    Verberk WJ, Kroon AA, Kessels AG, et al. Home blood pressure measurement: a systematic review. J Am Coll Cardiol 2005; 46: 743–51.PubMedGoogle Scholar
  102. 102.
    Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1. Blood pressure measurement in humans — a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111:697–716.PubMedGoogle Scholar
  103. 103.
    Verberk WJ, Kroon AA, Kessels AG, et al. Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: a randomized, controlled trial. Home versus office measurement, reduction of unnecessary treatment study investigators. Hypertension 2007; 50: 1019–25.PubMedGoogle Scholar
  104. 104.
    Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. Blood Pressure Lowering Treatment Trialists’ Collaboration. J Hypertens 2007; 25: 951–8.PubMedGoogle Scholar
  105. 105.
    Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the reninangiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026–33.PubMedGoogle Scholar
  106. 106.
    Sica DA. Combination ACE inhibitor and angiotensin receptor blocker therapy: future considerations. J Clin Hypertens (Greenwich) 2007; 9: 78–86.Google Scholar
  107. 107.
    Patel A, McMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. ADVANCE Collaborative Group. Lancet 2007; 370: 829–40.PubMedGoogle Scholar
  108. 108.
    Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ADVANCE Collaborative Group. N Engl J Med 2008; 358 (24): 2560–72.PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Nicolas W. Shammas
    • 1
    Email author
  • Domenic A. Sica
    • 2
  • Peter P. Toth
    • 1
    • 3
    • 4
  1. 1.Midwest Cardiovascular Research FoundationCardiovascular Medicine, PCDavenport
  2. 2.Division of Nephrology, Department of MedicineVirginia Commonwealth University Medical CenterRichmondUSA
  3. 3.Sterling Rock Falls Clinic SterlingUSA
  4. 4.University of Illinois College of MedicinePeoriaUSA

Personalised recommendations